DE69920921D1 - Leptin vermittelte geninduktion - Google Patents

Leptin vermittelte geninduktion

Info

Publication number
DE69920921D1
DE69920921D1 DE69920921T DE69920921T DE69920921D1 DE 69920921 D1 DE69920921 D1 DE 69920921D1 DE 69920921 T DE69920921 T DE 69920921T DE 69920921 T DE69920921 T DE 69920921T DE 69920921 D1 DE69920921 D1 DE 69920921D1
Authority
DE
Germany
Prior art keywords
leptin
induced
genes
adenylate cyclase
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69920921T
Other languages
English (en)
Other versions
DE69920921T2 (de
Inventor
Dani L Broekaert
Stefaan Vandekerckhove
Annick Verhee
Wim Waelput
Jan Tavernier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Instituut voor Biotechnologie VIB filed Critical Vlaams Instituut voor Biotechnologie VIB
Publication of DE69920921D1 publication Critical patent/DE69920921D1/de
Application granted granted Critical
Publication of DE69920921T2 publication Critical patent/DE69920921T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69920921T 1998-07-28 1999-07-27 Leptin vermittelte geninduktion Expired - Lifetime DE69920921T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98202524 1998-07-28
EP98202524 1998-07-28
PCT/EP1999/005489 WO2000007014A2 (en) 1998-07-28 1999-07-27 Leptin-mediated gene-induction

Publications (2)

Publication Number Publication Date
DE69920921D1 true DE69920921D1 (de) 2004-11-11
DE69920921T2 DE69920921T2 (de) 2006-03-09

Family

ID=8233981

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920921T Expired - Lifetime DE69920921T2 (de) 1998-07-28 1999-07-27 Leptin vermittelte geninduktion

Country Status (8)

Country Link
US (1) US7291458B2 (de)
EP (1) EP1101112B1 (de)
JP (1) JP2002521496A (de)
AT (1) ATE278952T1 (de)
AU (1) AU756617B2 (de)
CA (1) CA2335107C (de)
DE (1) DE69920921T2 (de)
WO (1) WO2000007014A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2335107C (en) 1998-07-28 2010-01-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
US7803765B2 (en) 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
AU8178401A (en) 2000-05-22 2001-12-03 Vlaams Interuniv Inst Biotech Receptor-based interaction trap
JPWO2002101034A1 (ja) * 2001-06-08 2004-09-24 ゾイジーン株式会社 レプチン誘導遺伝子
CA2452353C (en) * 2001-07-03 2012-06-12 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Reversed mammalian protein-protein interaction trap
EP1754052B1 (de) * 2004-06-03 2015-07-22 Phylogica Limited Modulatoren biochemischer eigenschaften
US7575878B2 (en) 2004-11-18 2009-08-18 Vib Vzw Methods of inhibiting leptin-induced signaling with fibronectin III domain antibodies
US8716220B2 (en) * 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
EP2074138A4 (de) 2006-09-19 2009-12-30 Phylogica Ltd Neuroprotektive peptidinhibitoren der ap-1-signalvermittlung und anwendungen davon
WO2008154700A1 (en) 2007-06-20 2008-12-24 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith
CA2725143A1 (en) * 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
GB201504859D0 (en) 2015-03-23 2015-05-06 Vib Vzw Viral particle based small molecule-protein interaction trap

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521066A (en) 1993-09-13 1996-05-28 Bristol-Myers Squibb Company Periplasmic membrane-bound system for detecting protein-protein interactions
US5716622A (en) * 1995-01-06 1998-02-10 The Rockefeller University Functionally active regions of signal transducer and activators of transcription
US5712149A (en) * 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
GB9511935D0 (en) 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
US5972621A (en) * 1995-11-27 1999-10-26 Millennium Pharmaceuticals, Inc. Methods of identifying compounds that modulate body weight using the OB receptor
WO1997020933A2 (en) 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
EP0882128A1 (de) * 1996-02-23 1998-12-09 Ariad Pharmaceuticals, Inc. Auf zellen basierendes testverfahren
JP2000511406A (ja) * 1996-04-22 2000-09-05 メルク エンド カンパニー インコーポレーテッド レプチンアッセイ
IL127153A0 (en) 1996-06-06 1999-09-22 Smithkline Beecham Plc Fragments of leptin (ob protein)
JP2000514422A (ja) * 1996-06-20 2000-10-31 メルク エンド カンパニー インコーポレーテッド 肥満のための遺伝子治療
US6001816A (en) * 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
EP0954579A1 (de) * 1996-06-20 1999-11-10 Merck & Co., Inc. Gentherapie gegen Fettleibigkeit
US5843697A (en) * 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
US5776689A (en) * 1996-07-19 1998-07-07 The Regents Of The University Of California Protein recruitment system
PL332458A1 (en) * 1996-09-20 1999-09-13 Hoechst Ag Application of leptin antagonists in treating insulin resistance in cases of diabeted of type ii
AU4789297A (en) * 1996-11-01 1998-05-29 Smithkline Beecham Plc Method for the detection of compounds that modulate the effects of the obese (ob) protein
US6294330B1 (en) * 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6342345B1 (en) * 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
AU8405998A (en) 1997-07-15 1999-02-10 Aurora Biosciences Corporation Compositions and methods for identifying modulators of transducisomes, a ew class of therapeutic targets
US5885779A (en) * 1997-09-09 1999-03-23 University Of British Columbia Repressed trans-activator system for characterization of protein-protein interactions
AU2668699A (en) 1998-02-11 1999-08-30 Beth Israel Deaconess Medical Center Methods and compositions for modulating leptin activity
CA2335107C (en) 1998-07-28 2010-01-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
CA2337086A1 (en) * 1998-07-28 2000-02-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Eukaryotic cell-based gene interaction cloning
AU5143099A (en) 1998-07-30 2000-02-21 Universite De Montreal Protein fragment complementation assays for the detection of biological or drug interactions
WO2001096538A2 (en) * 2000-06-13 2001-12-20 Bayer Aktiengesellschaft Regulation of human transmembrane serine protease
ATE374213T1 (de) 2000-11-14 2007-10-15 Vlaams Interuniv Inst Biotech Funktionelles fragment des leptinrezeptors
KR20030074788A (ko) 2001-02-06 2003-09-19 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질 렙틴

Also Published As

Publication number Publication date
CA2335107C (en) 2010-01-19
US7291458B2 (en) 2007-11-06
AU5508499A (en) 2000-02-21
JP2002521496A (ja) 2002-07-16
CA2335107A1 (en) 2000-02-10
EP1101112A2 (de) 2001-05-23
AU756617B2 (en) 2003-01-16
WO2000007014A2 (en) 2000-02-10
US20030036526A1 (en) 2003-02-20
ATE278952T1 (de) 2004-10-15
DE69920921T2 (de) 2006-03-09
WO2000007014A3 (en) 2000-04-27
EP1101112B1 (de) 2004-10-06

Similar Documents

Publication Publication Date Title
DE69920921D1 (de) Leptin vermittelte geninduktion
Jinushi et al. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid
Prescott et al. Nuclear-cytoplasmic interaction in DNA synthesis
MY120841A (en) Methods of inducing cancer cell death and tumor regression
GEP20032954B (en) Heterocyclic Inhibitors of P38
DK0584136T3 (da) Bestemmelse af peptidmotiver på MHC-molekyler
BG102259A (en) Compostions with controlled paroxetine release
PT633941E (pt) Promotores eurocarioticos sinteticos contendo dois elementos indutiveis
WO2002028381A3 (en) Methods of inducing cancer cell death and tumor regression
ES2152313T3 (es) Gen grb-3-3, sus variantes y sus utilizaciones.
PT914419E (pt) Ratinhos transgenicos capazes de expressar o factor de inibicao de leucemia
DE69223237T2 (de) Zusammensetzungen von zerspanbaren messing
ATE120209T1 (de) Isolierung von einkettigen proteinen mit fsh unter- drückender aktivität aus follikularflüssigkeit.
ATE221124T1 (de) Kombinationsvektoren zum austragen von genmaterial
ATE302215T1 (de) Modulatoren von intrazellulären entzündungs-, zelltod- und zellüberlebenswegen, die card- und kinase-domänen enthalten
HK1005886A1 (en) Expression signal-peptide-free staphylokinases
DK0548177T3 (da) 5-Aminosalicylsyrederivater til terapi af kroniske inflammatoriske tarmsygdomme
BR0009128A (pt) Uso de inulina em produtos de carne isentos deadjuvante de fospato e, produto de carne isentode adjuvante de fosfato
BG104119A (en) A new composition
CA2220012A1 (en) Methods for modulating t cell survival by modulating bcl-xl protein level
USD150872S (en) Necklace or similar article
USD160297S (en) Combined service signal and napkin holder
Reddy et al. Pattern of protein profiles of reproductive organs after induced bilateral cryptorchidism in albino rats
BG103627A (en) New ifn receptor 1-binding proteins, dna encoding them, and methods for the modulation of a cellular response for interferons
Wicks et al. It has been known for several years that glucagon elevates the activity of a few enzymes in rat liver. When it was discovered that cyclic AMP mediated the

Legal Events

Date Code Title Description
8364 No opposition during term of opposition